Australia closer to funding Alexion's A$500,000 rare disease drug
This article was originally published in Scrip
Executive Summary
Australia is getting close to making a decision on whether it will fund Alexion Pharmaceuticals' terminal complement inhibitor, Soliris (eculizumab), for the orphan disease paroxysmal nocturnal haemoglobinuria (PNH), through its Life Saving Drugs Program (LSDP). PNH, which affects some 75 Australians, is a very rare blood disorder that destroys red blood cells.